Founded in October 2023, Lead Healthcare is a benchmark project for the industrialization of scientific and technological achievements of Guangzhou Laboratory. The company focuses on the independent R&D of AI-enabled high-end life science instruments and bio-manufacturing equipment, and builds supporting ecological systems such as artificial intelligence (AI) algorithm systems, committed to providing microfluidic, automated, intelligent, and system-level solutions for the life science instrument field.

The core team at Lead Healthcare brings together a unique blend of expertise, combining technical R&D experience from Huawei, industrial know-how from United Imaging Healthcare, and academic excellence from ETH Zurich. This rare “academia-technology-industry” background has enabled the company to transform 22 laboratory patents into practical applications, while independently filing 57 patents and 10 software copyrights.

These efforts were recognized by the China National Intellectual Property Administration (CNIPA), which selected Lead Healthcare as one of the first batch of outstanding patent transformation cases—a distinction awarded to only 20 companies nationwide.

The company has also developed the industry’s first active single-cell sequencing system for the cell industry chain. This innovation was featured at the 2024 World Economic Forum Annual Meeting in Davos and has already garnered orders exceeding 10 million CNY from leading institutions such as West China Hospital and GenScript.

China's supply chain in the fields of scientific instruments and biopharmaceutical equipment remains highly vulnerable, with a localization rate of less than 20%. This heavy reliance on imports creates significant “chokepoint” risks, underscoring an urgent need for breakthroughs in domestic capabilities.

In response, the Chinese government has prioritized the localization of scientific instruments. The 14th Five-Year Plan explicitly emphasizes strengthening the R&D and manufacturing of high-end scientific instruments and equipment, with the goal of achieving independent and controllable technological development.

Regarding this round of capital raising, Feng Zhang, Founder and CEO of Lead Healthcare, stated: "We are very grateful for the trust and support of all investors! The completion of this angel round capital raising is of great significance to Lead Healthcare. It not only injects sufficient funds into Lead Healthcare's technological R&D and product industrialization, but also represents the capital market's high recognition of Lead Healthcare's development direction in the field of life science instruments and bio-manufacturing equipment."

Hongjia Gong, Founder of Jiadao Private Capital, Co-Founder of Hikvision(SZ: 002415), and Chairman of Vcan Bio(SH: 600645), said: "The technical strength and innovative potential demonstrated by Lead Healthcare in the field of life science instruments and bio-manufacturing equipment are remarkable. We believe that through this investment, Lead Healthcare will continue to deepen its presence in the industry and create greater value. We also look forward to in-depth cooperation between Lead Healthcare and Jiadao Private Capital in biopharmaceutical ecological chain enterprises to jointly promote technological progress and industrial development in the biopharmaceutical field."

Addressing the industry pain point of insufficient localization rate of scientific instruments, LILY ZHANG, Founding and Managing Partner of TTM Capital, stated: "Lead Healthcare has achieved technological breakthroughs in the field of life science instruments and bio-manufacturing equipment, and its independently developed products such as the active single-cell sequencing system are industry firsts. TTM Capital will leverage its own ecological resources in the healthcare industry to assist the company in connecting with downstream pharmaceutical companies and clinical institutions, and accelerate the commercialization of patented technologies."

This strategic investment demonstrates TTM Capital's in-depth layout in the field of high-end medical equipment. During the current critical window period of accelerated localization of scientific instruments, Lead Healthcare, with its core technological breakthroughs and industrialization capabilities, has formed strategic synergy with TTM Capital's investment philosophy of "driving industrial upgrading through technological innovation".

As a long-term value investor, TTM Capital will continue to leverage the dual-driver advantage of "capital + industry": on the one hand, it will deploy early investments in innovative enterprises with technological barriers; on the other hand, it will rely on rich industrial resources to provide portfolio companies with full-cycle empowerment from R&D to commercialization. We look forward to helping build an independent and controllable industrial chain for life science equipment through such an investment strategy, and promoting the high-quality development of China's healthcare industry.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.